Robeco Institutional Asset Management B.V. cut its position in LHC Group, Inc. (NASDAQ:LHCG) by 33.5% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 48,714 shares of the health services provider’s stock after selling 24,574 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 0.27% of LHC Group worth $2,998,000 at the end of the most recent quarter.
A number of other large investors have also recently modified their holdings of LHCG. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its stake in LHC Group by 558.3% during the 4th quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 200,000 shares of the health services provider’s stock valued at $12,250,000 after buying an additional 169,620 shares during the period. Allianz Asset Management GmbH increased its stake in LHC Group by 148.2% during the 4th quarter. Allianz Asset Management GmbH now owns 125,263 shares of the health services provider’s stock valued at $7,673,000 after buying an additional 74,793 shares during the period. Lombard Odier Asset Management Switzerland SA acquired a new position in LHC Group during the 4th quarter valued at about $3,553,000. Renaissance Technologies LLC increased its stake in LHC Group by 1,862.8% during the 4th quarter. Renaissance Technologies LLC now owns 184,500 shares of the health services provider’s stock valued at $11,301,000 after buying an additional 175,100 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its stake in LHC Group by 194.5% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 64,500 shares of the health services provider’s stock valued at $3,951,000 after buying an additional 42,600 shares during the period. Hedge funds and other institutional investors own 93.93% of the company’s stock.
Shares of LHC Group traded up $1.12, hitting $83.40, during midday trading on Thursday, according to MarketBeat.com. The stock had a trading volume of 249,300 shares, compared to its average volume of 293,183. LHC Group, Inc. has a fifty-two week low of $56.76 and a fifty-two week high of $83.45. The stock has a market cap of $1.46 billion, a price-to-earnings ratio of 34.46, a PEG ratio of 1.27 and a beta of 0.68. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.65 and a quick ratio of 1.65.
LHC Group (NASDAQ:LHCG) last announced its earnings results on Wednesday, May 2nd. The health services provider reported $0.63 EPS for the quarter, topping the consensus estimate of $0.60 by $0.03. The company had revenue of $291.10 million during the quarter, compared to analysts’ expectations of $295.21 million. LHC Group had a net margin of 4.07% and a return on equity of 9.29%. The business’s revenue for the quarter was up 19.2% on a year-over-year basis. During the same period last year, the company posted $0.53 earnings per share. analysts anticipate that LHC Group, Inc. will post 3.5 earnings per share for the current year.
Several equities analysts have recently issued reports on the stock. BidaskClub raised shares of LHC Group from a “sell” rating to a “hold” rating in a research note on Wednesday, April 4th. Zacks Investment Research raised shares of LHC Group from a “hold” rating to a “strong-buy” rating and set a $70.00 price objective on the stock in a research note on Tuesday, March 6th. Stephens set a $74.00 price objective on shares of LHC Group and gave the stock a “buy” rating in a research note on Friday, March 2nd. Craig Hallum lifted their price objective on shares of LHC Group from $70.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, April 4th. Finally, ValuEngine raised shares of LHC Group from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. LHC Group presently has an average rating of “Buy” and a consensus target price of $77.33.
In related news, insider Joshua L. Proffitt sold 10,556 shares of the firm’s stock in a transaction that occurred on Thursday, May 17th. The shares were sold at an average price of $75.20, for a total transaction of $793,811.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Jeff Reibel sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 10th. The stock was sold at an average price of $72.35, for a total transaction of $217,050.00. Following the sale, the senior vice president now owns 12,546 shares of the company’s stock, valued at $907,703.10. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 16,863 shares of company stock valued at $1,274,628. 6.80% of the stock is currently owned by corporate insiders.
LHC Group Company Profile
LHC Group, Inc, a health care provider, specializes in the post-acute continuum of care primarily for Medicare beneficiaries in the United States. The company operates through four segments: Home Health Services, Hospice Services, Community-Based Services, and Facility-Based Services. The Home Health Services segment offers home nursing services, including wound care and dressing changes, cardiac rehabilitation, infusion therapy, pain management, pharmaceutical administration, skilled observation and assessment, and patient education; medically-oriented social services; and physical, occupational, and speech therapy services.
Receive News & Ratings for LHC Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LHC Group and related companies with MarketBeat.com's FREE daily email newsletter.